STLN (Starling Oncology) Institutional Ownership: 38.48% (As of Aug. 05, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STLN Starling Oncology Inc STLN
56 GF Score
Price $5.17
GF Value $2.29
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Starling Oncology Institutional Ownership?

Starling Oncology STLN +5.56% 56 Institutional Ownership is 38.48% as of Aug. 05, 2026. GuruFocus rates STLN with a GF Score™ of 56/100 and a GF Value™ of $2.29 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Starling Oncology's institutional ownership is 38.48%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Starling Oncology's Insider Ownership is 8.85%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Starling Oncology's Float Percentage Of Total Shares Outstanding is 87.67%.

Starling Oncology Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Starling Oncology's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Starling Oncology Institutional Ownership Chart

Starling Oncology Historical Data

The historical data trend for Starling Oncology can be seen below:

2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31
Institutional Ownership 12.75 12.92 14.30 13.99 14.03 15.38 15.26 15.57 15.61 16.32
STLN
56GF Score
Starling Oncology Inc STLN
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Starling Oncology Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 38.48% mean?
Starling Oncology (STLN) has a Institutional Ownership of 38.48% as of Aug. 05, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Starling Oncology and its competitors.
Is Starling Oncology's Institutional Ownership too high?
Starling Oncology's current Institutional Ownership is 38.48%. Overall, Starling Oncology has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Starling Oncology's Institutional Ownership compare to SRTA and CCRN?
Starling Oncology's Institutional Ownership of 38.48% can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Healthcare Providers & Services company?
A good Institutional Ownership depends on the Healthcare Providers & Services industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Starling Oncology and its competitors. Starling Oncology's current Institutional Ownership is 38.48%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Starling Oncology stock overvalued right now?
Based on GuruFocus' analysis, Starling Oncology (STLN) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.29, compared to a current price of $5.17 — trading 125.8% above its estimated fair value. The current Institutional Ownership is 38.48%. Starling Oncology's overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Starling Oncology (STLN), the current Institutional Ownership is 38.48% as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Starling Oncology (STLN) Overvalued in 2026?

Based on GuruFocus' analysis, Starling Oncology stock appears to be overvalued. The current stock price of $5.17 is trading 125.8% above its estimated GF Value™ of $2.29. GuruFocus considers Starling Oncology to be Significantly Overvalued.

Key valuation signals for STLN:

  • Institutional Ownership: 38.48%
  • GF Value™: $2.29 vs. price of $5.17 (125.8% above fair value)
  • GF Score™: 56/100 with 4 warning signs

No single metric tells the full story. See the STLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Starling Oncology Business Description

Address 18000 Studebaker Road, Suite 800, Cerritos, CA, USA, 90703
The Oncology Institute Inc offers oncology care and treatment services to patients through several clinics located across the United States. It offers services such as infusion chemotherapy, oral drug chemotherapy, hospice and palliative care, autologous stem cell transplants, outpatient blood product transfusions, patient navigator programs, radiation oncology, and others on a fee or value-based model. Additionally, the company enrolls patients in clinical trials, where appropriate. The company has three operating segments: Specialty Pharmacy, Patient Services, and Clinical Trials and Other. Maximum revenue is generated from the Specialty Pharmacy segment, which operates specialty and retail pharmacies providing IV-infused, oral, injectable, and other medications for oncology treatment.
56GF Score

Get the complete analysis for STLN

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.17
Price
$2.29
GF Value